[Congressional Bills 105th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2197 Introduced in House (IH)]







105th CONGRESS
  1st Session
                                H. R. 2197

To amend title 38, United States Code, to specify the entities eligible 
 to purchase pharmaceutical products from the Federal Supply Schedule.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             July 17, 1997

  Mr. Stearns (for himself, Mr. Gutierrez, Mr. Stump, and Mr. Evans) 
 introduced the following bill; which was referred to the Committee on 
                           Veterans' Affairs

_______________________________________________________________________

                                 A BILL


 
To amend title 38, United States Code, to specify the entities eligible 
 to purchase pharmaceutical products from the Federal Supply Schedule.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. PURCHASES OF PHARMACEUTICAL PRODUCTS.

    Section 8125 of title 38, United States Code, is amended--
            (1) by redesignating subsection (e) as subsection (f); and
            (2) by inserting after subsection (d) the following new 
        subsection (e):
    ``(e)(1) A drug, pharmaceutical product, or hematology-related 
product that is listed on the pharmaceutical supply schedule described 
in section 8126(a) of this title may only be procured or ordered from 
that supply schedule by or for any entity specified in paragraph (2), 
notwithstanding any other provision of law (whether enacted before, on, 
or after the date of the enactment of this subsection).
    ``(2) An entity specified in this paragraph is (A) any agency or 
instrumentality of the Federal Government, or (B) any other entity that 
is specified in Federal law or regulation, as in effect before July 1, 
1997, as eligible to procure or order drugs, pharmaceutical products, 
or hematology-related products from such pharmaceutical supply 
schedule.''.
                                 <all>